SCHEMBL6577904

SCHEMBL6577904

Cc1c(CCN)c2cc(S(=O)(=O)c3ccc(C(F)(F)F)cc3)ccc2n1C

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 9/20 0.47
PARG Q86W56 1/20 0.36
KIF11 P52732 1/20 0.36
TAAR1 Q96RJ0 1/20 0.35
BCHE P06276 1/20 0.35
ACHE P22303 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.34
PIK3CG P48736 1/20 0.34
SPR P35270 1/20 0.34
USP2 O75604 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6577960 0.99 HTR6 (0.46) HTR6PARGKIF11TAAR1BCHE
SCHEMBL6577810 0.87 GAA (0.41) HTR6PTGDR2PIK3CGSPRUSP2
SCHEMBL6577239 0.87 HTR6 (0.46) HTR6PARGKIF11BCHEACHE
Hydrochloric Acid SCHEMBL6580196 0.86 GAA (0.40) HTR6PTGDR2PIK3CGSPRUSP2
SCHEMBL6575479 0.86 HTR6 (0.48) HTR6ALDH1A1
Hydrochloric Acid SCHEMBL6579605 0.86 HTR6 (0.45) HTR6PARGKIF11BCHEACHE
Hydrochloric Acid SCHEMBL6577375 0.85 HTR6 (0.48) HTR6ALDH1A1
SCHEMBL6575514 0.84 HTR6 (0.45) HTR6PTGDR2PIK3CGSPR
Hydrochloric Acid SCHEMBL6577886 0.83 HTR6 (0.44) HTR6PTGDR2PIK3CGSPR
SCHEMBL6577381 0.82 HTR6 (0.48) HTR6PARGKIF11BCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6565829-B2 Psychological disorders; central nervous system disorders PHARMACIA & UPJOHN COMPANY 2003-05-20 US claimed
US-20030060498-A1 5-arylsulfonyl indoles useful for treating disease PHARMACIA & UPJOHN COMPANY 2003-03-27 US claimed
EP-1411925-A1 5-ARYLSULFONYL INDOLES HAVING 5-HT6 RECEPTOR AFFINITY PHARMACIA & UPJOHN COMPANY (US) 2004-04-28 EP disclosed
US-6565829-B2 Psychological disorders; central nervous system disorders PHARMACIA & UPJOHN COMPANY 2003-05-20 US disclosed
US-20030060498-A1 5-arylsulfonyl indoles useful for treating disease PHARMACIA & UPJOHN COMPANY 2003-03-27 US disclosed
WO-2003011284-A1 5-ARYLSULFONYL INDOLES HAVING 5-HT6 RECEPTOR AFFINITY PHARMACIA & UPJOHN COMPANY (US) 2003-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060498-A1 5-arylsulfonyl indoles useful for treating disease IDO1, HTR5A, IDO2 HTR6 14/4885PARG 4416/4885KIF11 3616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.